Celldex Therapeutics Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report issued on Monday. They presently have a $9.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 117.39% from the company’s current price.

The analysts wrote, “Celldex Receives a Buy from Cantor Fitzgerald | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h */

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/celldex-therapeutics-cldx-buy-rating-reaffirmed-at-cantor-fitzgerald.html

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘http://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=ae16fd92b5&wpp_id=456014’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
/* Send request */
xhr.send( params );


(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;


Stock Market
Best Performing Analysts

Basic Materials
Consumer Goods
Industrial Goods

Most Popular
Contact Us

Home » Celldex Receives a Buy from Cantor Fitzgerald”

Several other research analysts have also recently commented on CLDX. Wedbush reiterated a “neutral” rating and issued a $3.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Jefferies Group reiterated a “hold” rating and issued a $5.00 price target (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Finally, Brean Capital assumed coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They issued a “buy” rating and a $16.00 price target on the stock. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $7.75.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 0.72% on Monday, hitting $4.17. The company’s stock had a trading volume of 949,691 shares. The firm’s market cap is $419.27 million. The company has a 50 day moving average of $3.75 and a 200 day moving average of $4.17. Celldex Therapeutics has a 1-year low of $2.96 and a 1-year high of $18.62.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The business had revenue of $1.39 million for the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue was down 36.4% compared to the same quarter last year. Equities analysts forecast that Celldex Therapeutics will post ($1.34) EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Celldex Therapeutics by 4.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 373,066 shares of the biopharmaceutical company’s stock valued at $1,638,000 after buying an additional 14,300 shares during the period. Alps Advisors Inc. raised its position in Celldex Therapeutics by 24.9% in the second quarter. Alps Advisors Inc. now owns 138,680 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 27,677 shares during the period. Bank of Montreal Can bought a new position in Celldex Therapeutics during the second quarter valued at approximately $188,000. Marcus Capital LLC raised its position in Celldex Therapeutics by 58.5% in the second quarter. Marcus Capital LLC now owns 111,600 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 41,200 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Celldex Therapeutics by 2.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,903 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 1,412 shares during the period. 78.41% of the stock is owned by institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

5 Day Chart for NASDAQ:CLDX

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.